New data on ARIAD's AP24534 and ridaforolimus accepted for presentation at ASCO 2010

ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced that new data on AP24534, its investigational pan-BCR-ABL inhibitor, and ridaforolimus, its investigational mTOR inhibitor being developed by Merck, Sharpe & Dohme Corp., have been accepted for presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Illinois being held June 4 to 8, 2010.

The schedule and meeting location for the sessions, together with the abstract information, are listed below by program:

AP24534

Title: Phase 1 trial of AP24534 in patients with refractory chronic myeloid leukemia (CML) and other hematologic malignancies
Date & Time: Monday, June 7, 2010, 2:00 PM - 6:00 PM (with presentation at 5:00 PM)
Abstract: #53232
Presenter: Moshe Talpaz, M.D. (University of Michigan)
Location: Exhibit Hall, 354a

Ridaforolimus

Title: A phase 1 study of the oral mTOR inhibitor ridaforolimus (RIDA) in combination with the IGF-1R antibody dalotuzumab (DALO) in patients (pts) with advanced solid tumors
Date & Time: Saturday, June 5, 2010, 1:30 PM - 2:00 PM
Abstract: #48347
Presenter: Serena Di Cosimo, M.D. (Breast Cancer Center, Vall d'Hebron University Hospital)
Location: Exhibit Hall, D2

Title: A multi-center, first-in-pediatrics phase 1 study of ridaforolimus (AP23573, MK-8669) in patients (pts) with refractory solid tumors
Date & Time: Sunday, June 6, 2010, 5:00 PM - 6:00 PM
Abstract: #48828
Presenter: Lia Gore, M.D. (University of Colorado Denver and The Children's Hospital)
Location: Room S 504

Source ARIAD